within Pharmacolibrary.Drugs.ATC.N;

model N01BB52
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.5666666666666667,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.08,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Lidocaine is a local anesthetic and antiarrhythmic agent commonly used for local or regional anesthesia, and to treat ventricular arrhythmias. Combinations (ATC N01BB52) may include lidocaine with other agents to enhance anesthetic efficacy or provide multi-modal pain relief. It is widely approved for use in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adults (sex unspecified) based on known PK of lidocaine monotherapy, as there is no published data for precise PK in these combinations.</p><h4>References</h4><ol><li><p>Beaussier, M, et al., &amp; Mercadal, L (2018). Perioperative Use of Intravenous Lidocaine. <i>Drugs</i> 78(12) 1229–1246. DOI:<a href=&quot;https://doi.org/10.1007/s40265-018-0955-x&quot;>10.1007/s40265-018-0955-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30117019/&quot;>https://pubmed.ncbi.nlm.nih.gov/30117019</a></p></li><li><p>Hughes, LM, et al., &amp; Nestor, CC (2023). Alternatives to remifentanil for the analgesic component of total intravenous anaesthesia: a narrative review. <i>Anaesthesia</i> 78(5) 620–625. DOI:<a href=&quot;https://doi.org/10.1111/anae.15952&quot;>10.1111/anae.15952</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36562193/&quot;>https://pubmed.ncbi.nlm.nih.gov/36562193</a></p></li><li><p>van Haren, F, et al., &amp; Steegers, M (2020). Intravenous lidocaine affects oxaliplatin pharmacokinetics in simultaneous infusion. <i>Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners</i> 26(8) 1850–1856. DOI:<a href=&quot;https://doi.org/10.1177/1078155220905011&quot;>10.1177/1078155220905011</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32075507/&quot;>https://pubmed.ncbi.nlm.nih.gov/32075507</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N01BB52;
